Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a PET scan reveal who will respond to kidney cancer therapy?

NCT ID NCT07827482

Diagnosis Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are studying whether features from pretreatment 18F-FDG PET/CT scans can predict how well people with metastatic kidney cancer respond to first-line targeted therapy plus immunotherapy. The study reviews medical records and imaging data from 228 patients treated at a single hospital. It extracts imaging features from both the primary kidney tumor and metastatic lesions, then combines them into a model. Treatment response is measured about 12 weeks after starting therapy using standard criteria, and the study also looks at progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-FDG PET/CT imaging before treatment
What this could lead to
If imaging features predict who responds, doctors could use a PET/CT scan to choose the best treatment upfront for people with metastatic kidney cancer.
What could go wrong
This is a retrospective review of past records at one hospital, so the findings may not hold up in a prospective trial or apply to other settings. The imaging model may not predict response accurately enough to guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

228 people

The number who actually took part.

Started

Jun 2019

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with pathologically confirmed metastatic renal cell carcinoma who underwent pretreatment 18F-FDG PET/CT and received first-line axitinib plus pembrolizumab or toripalimab at the First Affiliated Hospital of Fujian Medical University. Eligible patients were identified retrospectively from institutional medical and imaging records. The study included patients with adequate clinical, pathological, imaging, treatment response, and follow-up data.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathologically confirmed metastatic renal cell carcinoma. 2. Pretreatment 18F-FDG PET/CT performed before initiation of first-line systemic therapy. 3. Receipt of first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor combination therapy. 4. At least one measurable lesion according to RECIST version 1.1. 5. Available clinicopathological, imaging, treatment response, and follow-up data. Exclusion Criteria: 1. Receipt of systemic anticancer therapy before the pretreatment 18F-FDG PET/CT examination. 2. An interval of more than 1 month between pretreatment PET/CT and initiation of first-line systemic therapy. 3. Unavailable treatment response assessment or follow-up data. 4. Incomplete key clinicopathological or imaging information. 5. PET/CT image quality inadequate for lesion segmentation or radiomics analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic renal cell carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic renal cell carcinoma

Contacts and locations

Locations

  • First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350005, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.